-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
FibroGen (NASDAQ:FGEN) Cut to "Hold" at StockNews.com
FibroGen (NASDAQ:FGEN) Cut to "Hold" at StockNews.com
StockNews.com lowered shares of FibroGen (NASDAQ:FGEN – Get Rating) from a buy rating to a hold rating in a report issued on Wednesday morning.
Separately, The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a sell rating for the company in a report on Tuesday, May 24th.
Get FibroGen alerts:FibroGen Stock Up 3.1 %
NASDAQ:FGEN opened at $14.49 on Wednesday. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91. The business's 50 day moving average is $11.81 and its two-hundred day moving average is $12.01.
FibroGen (NASDAQ:FGEN – Get Rating) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. The firm had revenue of $29.81 million during the quarter, compared to the consensus estimate of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm's revenue was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.45) earnings per share. As a group, equities analysts expect that FibroGen will post -3 EPS for the current year.Institutional Trading of FibroGen
A number of large investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in shares of FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after purchasing an additional 2,621,494 shares during the period. Soleus Capital Management L.P. bought a new stake in FibroGen during the 4th quarter valued at $21,862,000. Federated Hermes Inc. boosted its position in FibroGen by 84.1% during the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock worth $28,799,000 after acquiring an additional 1,094,403 shares during the period. First Trust Advisors LP grew its stake in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock worth $74,978,000 after purchasing an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock valued at $10,274,000 after purchasing an additional 748,230 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com lowered shares of FibroGen (NASDAQ:FGEN – Get Rating) from a buy rating to a hold rating in a report issued on Wednesday morning.
在週三上午發佈的一份報告中，斯托克新聞網將FibroGen(納斯達克代碼：FDEN-GET)的股票評級從買入下調至持有。
Separately, The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a sell rating for the company in a report on Tuesday, May 24th.
另外，高盛夫婦在5月24日週二的一份報告中將FibroGen的目標價從9.00美元下調至8.00美元，併為該公司設定了賣出評級。
FibroGen Stock Up 3.1 %
FibroGen股價上漲3.1%
NASDAQ:FGEN opened at $14.49 on Wednesday. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91. The business's 50 day moving average is $11.81 and its two-hundred day moving average is $12.01.
納斯達克：fgen週三開盤報14.49美元。FibroGen的52周低點為7.81美元，52周高位為16.91美元。該業務的50日移動均線切入位為11.81美元，200日移動均線切入位為12.01美元。
Institutional Trading of FibroGen
FibroGen的機構交易
A number of large investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in shares of FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after purchasing an additional 2,621,494 shares during the period. Soleus Capital Management L.P. bought a new stake in FibroGen during the 4th quarter valued at $21,862,000. Federated Hermes Inc. boosted its position in FibroGen by 84.1% during the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock worth $28,799,000 after acquiring an additional 1,094,403 shares during the period. First Trust Advisors LP grew its stake in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock worth $74,978,000 after purchasing an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock valued at $10,274,000 after purchasing an additional 748,230 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.
一些大型投資者最近調整了對該公司的持股。Point72 Asset Management L.P.在第四季度增持了235.9%的FibroGen股票。Point72 Asset Management L.P.在此期間額外購買了2,621,494股，現在擁有這家生物製藥公司3,732,594股股票，價值52,630,000美元。Soleus Capital Management L.P.在第四季度購買了FibroGen的新股份，價值21,862,000美元。聯合愛馬仕公司在第一季度將其在FibroGen的頭寸增加了84.1%。聯合愛馬仕公司目前持有這家生物製藥公司2,395,883股股票，價值28,799,000美元，在此期間又收購了1,094,403股。First Trust Advisors LP在第四季度增持了24.8%的FibroGen股票。First Trust Advisors LP現在擁有這家生物製藥公司5,317,613股股票，價值74,978,000美元，上個季度又購買了1,055,536股。最後，Assenagon Asset Management S.A.在第二季度增持了333.0%的FibroGen股票。Assenagon Asset Management S.A.在此期間又購買了748,230股票，現在擁有972,901股這家生物製藥公司的股票，價值10,274,000美元。機構投資者和對衝基金持有該公司77.35%的股票。
About FibroGen
關於FibroGen
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物製藥公司，發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat，該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發，並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- 值得關注的兩場重要的零售股大戰
- MarketBeat：回顧中的一週2012-8-8
- 什麼是WallStreetBets，他們的目標是什麼股票？
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎？
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧